- 1. CpG
- [A dinucleotide consisting of cytosine followed by guanine. ( NCI )] (UMLS (NCI) C0056912) =Nucleic Acid, Nucleoside, or Nucleotide; Biologically Active Substance
| - 5. CpG 7909/Trastuzumab
- (UMLS (NCI) C1134665) =Therapeutic or Preventive Procedure
|
- 2. CpG 7909
- [A synthetic 24-mer oligonucleotide containing 3 CpG motifs with potential antineoplastic and immunostimulatory activity. CpG 7909 selectively targets Toll-like receptor 9 (TLR9), thereby activating dendritic and B cells and stimulating cytotoxic T cell and antibody responses against tumor cells bearing tumor antigens. (NCI05) ( NCI )] (UMLS (NCI) C1134664) =Nucleic Acid, Nucleoside, or Nucleotide; Pharmacologic Substance ;
| - 6. CpG island
- [Short region of DNA in which the frequency of the CG sequence is higher than in other regions. ( NCI )] (UMLS (CSP) C0282523) =Nucleic Acid, Nucleoside, or Nucleotide; Biologically Active Substance =nucleic acid sequence;
|
- 3. CpG 7909/Dacarbazine
- (UMLS (NCI) C1328141) =Therapeutic or Preventive Procedure ;
| - 7. CpG ODN
- [A synthetic oligodeoxynucleotide containing multiple repeats of unmethylated CpG motifs (CpG ODN) with immunostimulatory activity. Upon entering the cell via endocytosis, CpG-28 activates numerous signaling transduction pathways resulting in the release of multiple cytokines. CpG-28 has immunomodulatory properties with direct activation of B-lymphocytes, dendritic and NK cells resulting in the stimulation of innate immunity and antibody-dependant cell cytotoxicity (ADCC). Additionally, this agent indirectly modulates T-cell responses though the release of cytokines (IL-12 and IFN gamma) to induce a preferential shift to the Th1 (helper) phenotype resulting in enhanced CD8+ cellular cytotoxicity. ( NCI )] (UMLS (NCI) C0914671) CpG oligodeoxynucleotide;
CpG-28;
CpG-28 Oligodeoxynucleotide;
=Nucleic Acid, Nucleoside, or Nucleotide; Pharmacologic Substance ;
|
- 4. CpG 7909/Rituximab
- (UMLS (NCI) C1134705) =Therapeutic or Preventive Procedure ;
| |
home
